Biogen (BIIB) announced it intends to invest an additional $2B in its existing manufacturing footprint in North Carolina’s Research Triangle Park, RTP. Biogen has invested approximately $10 billion in its North Carolina manufacturing footprint to date, including more than $3 billion in recent years, and this upcoming investment will fuel the continued advancement of Biogen’s late-stage clinical pipeline. In the next few years, Biogen plans to continue investing in multiple modalities and factories across the company’s two campuses in RTP. These investments will include further expansion of the antisense oligonucleotide capabilities and infrastructure, establishing clinical and commercial multi-platform fill finish capabilities, and continuing to modernize manufacturing technologies and controls through further advanced automation and artificial intelligence.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen assumed with Hold from Buy at Truist
- Fastly, Biogen, Kroger, Bloom, Pure: Insider Sell-Offs!
- Biogen’s New Study on Felzartamab: A Potential Game-Changer for IgAN Treatment
- Biogen’s Innovative Approach to SMA Treatment: The PIERRE-PK Study
- Biogen’s New Study on MS Drug Vumerity: Key Insights for Investors